GAMMA Investing’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$547K Sell
2,887
-38
-1% -$5.64K 0.02% 612
2026
Q1
$272K Buy
2,925
+16
+0.6% +$1.42K 0.01% 908
2025
Q4
$234K Buy
2,909
+69
+2% +$5.78K 0.01% 927
2025
Q3
$277K Buy
2,840
+68
+2% +$5.48K 0.02% 764
2025
Q2
$193K Buy
2,772
+1,196
+76% +$68.2K 0.01% 946
2025
Q1
$78.3K Buy
1,576
+742
+89% +$46.9K 0.01% 1454
2024
Q4
$58.3K Sell
834
-165
-17% -$13.7K 0.01% 1542
2024
Q3
$105K Buy
999
+271
+37% +$31.7K 0.01% 968
2024
Q2
$104K Buy
728
+462
+174% +$53.3K 0.01% 759
2024
Q1
$29.7K Buy
266
+139
+109% +$16.6K 0.01% 1379
2023
Q4
$16.5K Buy
+127
New +$17.5K ﹤0.01% 1619

Other funds holding ACLS

GAMMA Investing's ACLS Position: Q2 2026 in Review

GAMMA Investing reduced its Axcelis (ACLS) stake by 1.3% in Q2 2026, selling an estimated $5.64K and leaving 2,887 shares worth $547K. The position accounts for 0.02% of the portfolio, ranked #612.

GAMMA Investing first reported a position in ACLS in Q4 2023 and has held it in 11 quarters since. 40 funds tracked by Wall St. Rank hold ACLS as of Q2 2026.

  • GAMMA Investing held 2,887 shares of Axcelis worth $547K as of Q2 2026.
  • GAMMA Investing sold 38 Axcelis shares in Q2 2026, an estimated $5.64K.
  • Axcelis made up 0.02% of GAMMA Investing's portfolio in Q2 2026, its #612 holding.
  • GAMMA Investing first reported a position in Axcelis in Q4 2023 and has held it in 11 quarters since.
  • 40 funds tracked by Wall St. Rank held Axcelis as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.